Sigyn Therapeutics Files 8-K/A Amendment on Equity Sales
Ticker: SIGY · Form: 8-K/A · Filed: Oct 16, 2024 · CIK: 1642159
| Field | Detail |
|---|---|
| Company | Sigyn Therapeutics, Inc. (SIGY) |
| Form Type | 8-K/A |
| Filed Date | Oct 16, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $474,793, $4.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: equity-sale, amendment, sec-filing
TL;DR
Sigyn Therapeutics amended its 8-K filing regarding unregistered equity sales from Sept 30.
AI Summary
Sigyn Therapeutics, Inc. filed an amendment (Amendment No. 1) to its Form 8-K on October 16, 2024, reporting on unregistered sales of equity securities that occurred on September 30, 2024. The filing details the company's activities related to these sales, which are part of its ongoing operations.
Why It Matters
This amendment provides updated information regarding the company's issuance of equity, which can impact share structure and investor ownership.
Risk Assessment
Risk Level: medium — Amendments to 8-K filings, especially concerning unregistered equity sales, can indicate potential dilution or changes in the company's financial structure.
Key Players & Entities
- Sigyn Therapeutics, Inc. (company) — Registrant
- October 16, 2024 (date) — Filing Date
- September 30, 2024 (date) — Date of Earliest Event Reported
- 000-55575 (company) — SEC File Number
FAQ
What specific type of equity securities were sold in the unregistered offering?
The filing does not specify the exact type of equity securities sold, only that it pertains to 'Unregistered Sales of Equity Securities'.
What was the date of the earliest event reported in this amendment?
The earliest event reported was on September 30, 2024.
What is the Commission File Number for Sigyn Therapeutics, Inc.?
The Commission File Number is 000-55575.
What is the principal executive office address for Sigyn Therapeutics, Inc.?
The address of the principal executive office is 2468 Historic Decatur Road, Suite 140, San Diego, California 92106.
What is the purpose of filing an 8-K/A amendment?
An 8-K/A amendment is filed to correct or supplement information previously reported in an original 8-K filing.
Filing Stats: 638 words · 3 min read · ~2 pages · Grade level 12.4 · Accepted 2024-10-16 15:52:22
Key Financial Figures
- $474,793 — orm 8-K") reporting that the holders of $474,793 of Original Issue Discount Senior Conve
- $4.00 — n average contractual exercise price of $4.00 per share in exchange for the issuance
Filing Documents
- form8-ka.htm (8-K/A) — 38KB
- 0001493152-24-041285.txt ( ) — 237KB
- sigy-20241004.xsd (EX-101.SCH) — 3KB
- sigy-20241004_def.xml (EX-101.DEF) — 29KB
- sigy-20241004_lab.xml (EX-101.LAB) — 33KB
- sigy-20241004_pre.xml (EX-101.PRE) — 24KB
- form8-ka_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SIGYN THERAPEUTICS, INC. Date: October 16, 2024 By: /s/ James A. Joyce James A. Joyce, Chairman and CEO